Company News
Guggenheim Names ABIVAX Top Biotech Pick
Guggenheim Securities maintains a buy rating on ABIVAX Société Anonyme, naming it its top biotech pick ahead of ABTECT Part Two readout.
Guggenheim notes obefazimod’s skin cancer and non‑NMSC rates pe
